SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription
Abstract Background ChAdOx1 nCoV-19 is a recombinant adenovirus vaccine against SARS-CoV-2 that has passed phase III clinical trials and is now in use across the globe. Although replication-defective in normal cells, 28 kbp of adenovirus genes is delivered to the cell nucleus alongside the SARS-CoV-...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-03-01
|
Series: | Genome Medicine |
Online Access: | https://doi.org/10.1186/s13073-021-00859-1 |
id |
doaj-e1230c43536748bfa473cef2663111c6 |
---|---|
record_format |
Article |
spelling |
doaj-e1230c43536748bfa473cef2663111c62021-03-21T12:11:32ZengBMCGenome Medicine1756-994X2021-03-0113111710.1186/s13073-021-00859-1SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcriptionAbdulaziz Almuqrin0Andrew D. Davidson1Maia Kavanagh Williamson2Philip A. Lewis3Kate J. Heesom4Susan Morris5Sarah C. Gilbert6David A. Matthews7School of Cellular and Molecular Medicine, Faculty of Life Sciences, University Walk, University of BristolSchool of Cellular and Molecular Medicine, Faculty of Life Sciences, University Walk, University of BristolSchool of Cellular and Molecular Medicine, Faculty of Life Sciences, University Walk, University of BristolSchool of Cellular and Molecular Medicine, Faculty of Life Sciences, University Walk, University of BristolProteomics Facility, Faculty of Life Sciences, University Walk, University of BristolJenner Institute, Nuffield Department of Medicine, University of OxfordJenner Institute, Nuffield Department of Medicine, University of OxfordSchool of Cellular and Molecular Medicine, Faculty of Life Sciences, University Walk, University of BristolAbstract Background ChAdOx1 nCoV-19 is a recombinant adenovirus vaccine against SARS-CoV-2 that has passed phase III clinical trials and is now in use across the globe. Although replication-defective in normal cells, 28 kbp of adenovirus genes is delivered to the cell nucleus alongside the SARS-CoV-2 S glycoprotein gene. Methods We used direct RNA sequencing to analyse transcript expression from the ChAdOx1 nCoV-19 genome in human MRC-5 and A549 cell lines that are non-permissive for vector replication alongside the replication permissive cell line, HEK293. In addition, we used quantitative proteomics to study over time the proteome and phosphoproteome of A549 and MRC5 cells infected with the ChAdOx1 nCoV-19 vaccine. Results The expected SARS-CoV-2 S coding transcript dominated in all cell lines. We also detected rare S transcripts with aberrant splice patterns or polyadenylation site usage. Adenovirus vector transcripts were almost absent in MRC-5 cells, but in A549 cells, there was a broader repertoire of adenoviral gene expression at very low levels. Proteomically, in addition to S glycoprotein, we detected multiple adenovirus proteins in A549 cells compared to just one in MRC5 cells. Conclusions Overall, the ChAdOx1 nCoV-19 vaccine’s transcriptomic and proteomic repertoire in cell culture is as expected. The combined transcriptomic and proteomics approaches provide a detailed insight into the behaviour of this important class of vaccine using state-of-the-art techniques and illustrate the potential of this technique to inform future viral vaccine vector design.https://doi.org/10.1186/s13073-021-00859-1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Abdulaziz Almuqrin Andrew D. Davidson Maia Kavanagh Williamson Philip A. Lewis Kate J. Heesom Susan Morris Sarah C. Gilbert David A. Matthews |
spellingShingle |
Abdulaziz Almuqrin Andrew D. Davidson Maia Kavanagh Williamson Philip A. Lewis Kate J. Heesom Susan Morris Sarah C. Gilbert David A. Matthews SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription Genome Medicine |
author_facet |
Abdulaziz Almuqrin Andrew D. Davidson Maia Kavanagh Williamson Philip A. Lewis Kate J. Heesom Susan Morris Sarah C. Gilbert David A. Matthews |
author_sort |
Abdulaziz Almuqrin |
title |
SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription |
title_short |
SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription |
title_full |
SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription |
title_fullStr |
SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription |
title_full_unstemmed |
SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription |
title_sort |
sars-cov-2 vaccine chadox1 ncov-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of sars-cov-2 s glycoprotein gene transcription |
publisher |
BMC |
series |
Genome Medicine |
issn |
1756-994X |
publishDate |
2021-03-01 |
description |
Abstract Background ChAdOx1 nCoV-19 is a recombinant adenovirus vaccine against SARS-CoV-2 that has passed phase III clinical trials and is now in use across the globe. Although replication-defective in normal cells, 28 kbp of adenovirus genes is delivered to the cell nucleus alongside the SARS-CoV-2 S glycoprotein gene. Methods We used direct RNA sequencing to analyse transcript expression from the ChAdOx1 nCoV-19 genome in human MRC-5 and A549 cell lines that are non-permissive for vector replication alongside the replication permissive cell line, HEK293. In addition, we used quantitative proteomics to study over time the proteome and phosphoproteome of A549 and MRC5 cells infected with the ChAdOx1 nCoV-19 vaccine. Results The expected SARS-CoV-2 S coding transcript dominated in all cell lines. We also detected rare S transcripts with aberrant splice patterns or polyadenylation site usage. Adenovirus vector transcripts were almost absent in MRC-5 cells, but in A549 cells, there was a broader repertoire of adenoviral gene expression at very low levels. Proteomically, in addition to S glycoprotein, we detected multiple adenovirus proteins in A549 cells compared to just one in MRC5 cells. Conclusions Overall, the ChAdOx1 nCoV-19 vaccine’s transcriptomic and proteomic repertoire in cell culture is as expected. The combined transcriptomic and proteomics approaches provide a detailed insight into the behaviour of this important class of vaccine using state-of-the-art techniques and illustrate the potential of this technique to inform future viral vaccine vector design. |
url |
https://doi.org/10.1186/s13073-021-00859-1 |
work_keys_str_mv |
AT abdulazizalmuqrin sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription AT andrewddavidson sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription AT maiakavanaghwilliamson sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription AT philipalewis sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription AT katejheesom sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription AT susanmorris sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription AT sarahcgilbert sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription AT davidamatthews sarscov2vaccinechadox1ncov19infectionofhumancelllinesrevealslowlevelsofviralbackbonegenetranscriptionalongsideveryhighlevelsofsarscov2sglycoproteingenetranscription |
_version_ |
1724210844556853248 |